---
title: "ANKE BIO simultaneously launches Phase III clinical trials for two new drugs for pediatric respiratory viral infections"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262791408.md"
description: "ANKE BIO held a Phase III clinical trial investigator meeting in Xiamen for two new drugs targeting respiratory viral infections in children, namely AK1012 inhalation solution and human interferon α2b spray. Both products are aimed at common diseases in children, with AK1012 being a modified new formulation designed to treat lower respiratory tract infections caused by respiratory syncytial virus, while the human interferon α2b spray is used for the treatment of herpetic pharyngitis in children"
datetime: "2025-10-27T00:16:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262791408.md)
  - [en](https://longbridge.com/en/news/262791408.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262791408.md)
---

# ANKE BIO simultaneously launches Phase III clinical trials for two new drugs for pediatric respiratory viral infections

ANKA BIO held the "AK1012 Inhalation Solution Phase II/III Clinical Trial Investigator Meeting" and the "Human Interferon α2b Spray Phase III Clinical Trial Investigator Meeting" in Xiamen, with both products focusing on respiratory viral infections in children entering the clinical validation sprint phase simultaneously. The two products that have initiated Phase III clinical trials target common and urgently needed disease areas in children. Among them, AK1012 Inhalation Solution is an improved new formulation of the company's already marketed product "Human Interferon α2b Injection," intended for the treatment of lower respiratory tract infections in children caused by respiratory syncytial virus. The Human Interferon α2b Spray is intended for the treatment of herpetic pharyngitis in children

### Related Stocks

- [300009.CN](https://longbridge.com/en/quote/300009.CN.md)

## Related News & Research

- [Rising Bond Yields Weigh on Stocks](https://longbridge.com/en/news/286939009.md)
- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [15:55 ETInception Fertility Launches MySpermBank, Expanding Access to Donor Sperm Services Nationwide](https://longbridge.com/en/news/287265370.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [15:21 ETTEAMSTERS AT BIMBO BAKERIES RATIFY NEW AGREEMENT](https://longbridge.com/en/news/286810426.md)